tolerogenic dendritic cells on transplantation: immunotherapy based on second signal blockage
Clicks: 101
ID: 236300
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
101 views
16 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #126 of 150 articles by views in journal of photochemistry and photobiology b, biology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 150 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Dendritic cells (DCs), the most important professional antigen-presenting cells (APC), play crucial role in both immunity and tolerance. It is well known that DCs are able to mount immune responses against foreign antigens and simultaneously tolerate self-antigens. Since DCs can be modulated depending on the surrounding microenvironment, they can act as a bridge between innate and adaptive immunity. However, the mechanisms that support this dual role are not entirely clear. Recent studies have shown that DCs can be manipulated ex vivo in order to trigger their tolerogenic profile, what can be a tool to be used in clinical trials aiming the treatment of various diseases and the prevention of transplant rejection. In this sense, the blockage of costimulatory molecules on DC, in the attempt of inhibiting the second signal in the immunological synapse, can be considered as one of the main strategies under development. This review brings an update on current therapies using tolerogenic dendritic cells modulated with costimulatory blockers with the aim of reducing transplant rejection. However, although there are current clinical trials using tolerogenic DC to treat allograft rejection, the actual challenge is to modulate these cells in order to maintain a permanent tolerogenic profile.
| Reference Key |
silva2015journaltolerogenic
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Priscila de Matos Silva;Julia Bier;Lisiery Negrini Paiatto;Cassia Galdino Albuquerque;Caique Lopes Souza;Luis Gustavo Romani Fernandes;Wirla Maria da Silva Cunha Tamashiro;Patricia Ucelli Simioni |
| Journal | journal of photochemistry and photobiology b, biology |
| Year | 2015 |
| DOI |
10.1155/2015/856707
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.